Zhen Su

Dr. Su has served as President & Chief Executive Officer of Marengo Therapeutics since July 2021, leading the company’s advancement as a clinical-stage oncology platform focused on next-generation precision immunotherapies. During his tenure, he has established strategic partnerships valued at over $3.5 billion, providing strong external validation of the company’s science and strategy while accelerating sustained pipeline and enterprise growth.
Dr. Su brings more than two decades of global biopharmaceutical leadership spanning R&D, commercialization, and franchise strategy. Prior to joining Marengo, he served as Senior Vice President and U.S. & Global Head of the Oncology Business Franchise at Merck KGaA, where he directed global oncology strategy and portfolio execution across major markets. Previously, as Chief Medical Officer of EMD Serono, he oversaw clinical development and medical affairs. He also held senior leadership roles at Sanofi and GSK.
Earlier in his career, Dr. Su was a physician-scientist at Duke University Medical School, leading early clinical studies in mRNA- and cell-based immunotherapy, and later served as Director of the Cell and Gene Therapy Program at the University
of Florida. Dr. Su currently serves on the Board of Directors of Karyopharm Therapeutics Inc. (Nasdaq: KPTI) and CytomX Therapeutics, Inc. (Nasdaq: CTMX), and has been a member of Marengo’s Board of Directors since 2021. He earned his M.D. from the Technical University of Dresden and his M.B.A. from the University of Toronto.